全文获取类型
收费全文 | 5887篇 |
免费 | 342篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 70篇 |
儿科学 | 393篇 |
妇产科学 | 78篇 |
基础医学 | 766篇 |
口腔科学 | 129篇 |
临床医学 | 438篇 |
内科学 | 1147篇 |
皮肤病学 | 123篇 |
神经病学 | 311篇 |
特种医学 | 190篇 |
外科学 | 829篇 |
综合类 | 310篇 |
一般理论 | 3篇 |
预防医学 | 335篇 |
眼科学 | 119篇 |
药学 | 562篇 |
1篇 | |
中国医学 | 40篇 |
肿瘤学 | 426篇 |
出版年
2023年 | 30篇 |
2022年 | 35篇 |
2021年 | 175篇 |
2020年 | 98篇 |
2019年 | 135篇 |
2018年 | 157篇 |
2017年 | 115篇 |
2016年 | 134篇 |
2015年 | 170篇 |
2014年 | 216篇 |
2013年 | 272篇 |
2012年 | 357篇 |
2011年 | 339篇 |
2010年 | 238篇 |
2009年 | 194篇 |
2008年 | 304篇 |
2007年 | 251篇 |
2006年 | 296篇 |
2005年 | 248篇 |
2004年 | 208篇 |
2003年 | 194篇 |
2002年 | 189篇 |
2001年 | 142篇 |
2000年 | 150篇 |
1999年 | 133篇 |
1998年 | 91篇 |
1997年 | 63篇 |
1996年 | 52篇 |
1995年 | 41篇 |
1994年 | 56篇 |
1993年 | 30篇 |
1992年 | 96篇 |
1991年 | 79篇 |
1990年 | 77篇 |
1989年 | 85篇 |
1988年 | 81篇 |
1987年 | 74篇 |
1986年 | 74篇 |
1985年 | 69篇 |
1984年 | 51篇 |
1983年 | 31篇 |
1982年 | 29篇 |
1981年 | 26篇 |
1980年 | 27篇 |
1979年 | 42篇 |
1977年 | 35篇 |
1975年 | 37篇 |
1974年 | 29篇 |
1972年 | 33篇 |
1971年 | 25篇 |
排序方式: 共有6270条查询结果,搜索用时 78 毫秒
1.
Smita Joshi Richard Muwonge Vinay Kulkarni Mahesh Mandolkar Eric Lucas Sanjay Pujari Rengaswamy Sankaranarayanan Partha Basu 《International journal of cancer. Journal international du cancer》2023,152(2):249-258
We are reporting (a) updated incidence of cervical intraepithelial neoplasia (CIN) among women who did not have colposcopic or histopathological disease at baseline and (b) disease outcomes among women treated for CIN and their follow-up HPV status; in a cohort of women living with HIV (WHIV). The median overall follow-up was 3.5 years (IQR 2.8-4.3). The incidence of any CIN and that of CIN 2 or worse disease was 16.7 and 7.0 per 1000 person-years of observation (PYO), respectively. Compared with women who were HPV negative at baseline, women who cleared HPV infection had 23.95 times increased risk of incident CIN 2 or worse lesions (95% CI 2.40-661.07). Women with persistent HPV infection had 138.18 times increased risk of CIN 2 or worse lesions (95% CI 20.30-3300.22). Complete disease regression was observed in 65.6% of the HPV positive women with high-grade CIN and were treated with thermal ablation but HPV persistence was seen in 44.8% of those with high-grade disease. Among those who did not have any disease at baseline and were also HPV negative, about 87% (95% CI 83.79-89.48) women remained HPV negative during consecutive HPV test/s with the median interval of 3.5 years. Long-term surveillance of WHIV treated for any CIN is necessary for the prevention of cervical cancer among them. Our study provides an early indication that the currently recommended screening interval of 3 to 5 years among WHIV may be extended to at least 5 years among HPV negative women. Increasing the screening interval can be cost saving and improve scalability among WHIV to support WHO's cervical cancer elimination initiative. 相似文献
2.
3.
4.
Hui Yu Zhengming Chen Karla V. Ballman Mark A. Watson Ramaswamy Govindan Irena Lanc David G. Beer Raphael Bueno Lucian R. Chirieac Michael Herman Chui Guoan Chen Wilbur A. Franklin David R. Gandara Carlo Genova Kristine A. Brovsky Mary-Beth M. Joshi Daniel T. Merrick William G. Richards Fred R. Hirsch 《Journal of thoracic oncology》2019,14(1):25-36
Objectives
Anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti–PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti–PD-1/PD-L1 immunotherapy–related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC.Methods
A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-γ) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens.Results
The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-γ gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-γ gene signatures were independently prognostic for patient outcomes.Conclusions
Evaluation of PD-L1 expression, TMB, and T-effector and IFN-γ gene signatures in the cohort with early-stage SqCLC found them to be independent of each other, and none was associated with overall survival. Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. 相似文献5.
Bindu Mulakavalupil Charudatta Vaity Shashank Joshi Anoop Misra Rahul Anil Pandit 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(4):102169
AimsWith a sudden increase in cases of mucormycosis seen in Covid ?19 patients, we conducted a retrospective analysis of all admitted patients in a tertiary care covid-19 hospital looking at incidence of mucormycosis.MethodsIntensive care unit daily rounds data stored in an electronic format was retrieved by one of the consultants, looking for incidence of mucormycosis, diabetes mellitus, adherence to protocol for steroid use, glycemic control and use of monoclonal antibodies. Also, patients follow up data base of post covid Outpatients Department was searched for cases of mucormycosis.ResultsA total of 5248 patients were admitted between March 2020 to May 2021, of which 1027 were in ICU and 4221 in wards. Of the 1027 patients admitted in Intensive care unit, 915 received steroids and 417 had diabetes as existing co-morbidity. No case of mucormycosis was reported during the stay in the hospital and during immediate outpatient department follow up. The low dose steroids were administered as per state government protocol for treating COVID 19, a nurse driven strict glycemic control regime (blood glucose level was maintained between 140 and 180 mg/dl through the admission in ICU and was achieved consistently in 842 (82%) patients, followed along with minimal use of other immunomodulatory like monoclonal antibodies.ConclusionA strict adherence to protocol of low dose steroids coupled with strict glycemic control helped in eliminating the risk and incidence of mucormycosis in a tertiary care dedicated covid-19 hospital. 相似文献
6.
7.
Arunaloke Chakrabarti Prashant Sood Shivaprakash M. Rudramurthy Sharon Chen Joseph Jillwin Ranganathan Iyer Ajanta Sharma Belgode Narasimha Harish Indranil Roy Anupma J. Kindo Deepinder Chhina Jayanthi Savio Deepak Mendiratta Malini R. Capoor Shukla Das Anita Arora Jagdish Chander Immaculata Xess Appalaraju Boppe Ujjwayini Ray Ratna Rao Vandana Kalwaje Eshwara Sangeeta Joshi Atul Patel Raman Sardana Anjali Shetty Umabala Pamidimukkala for the SIHAM Candidemia Network 《Mycoses》2020,63(11):1149-1163
8.
9.
Krishnakumar S. Kuris Snehalatha Kaveri Rachana Joshi Aditi Krishnakumar Rohan 《Journal of obstetrics and gynaecology of India》2020,70(3):237-239
The Journal of Obstetrics and Gynecology of India - 相似文献
10.
Govindaraj Saravanan Theivendren Panneerselvam Selvaraj Kunjiappan Pavadai Parasuraman Veerachamy Alagarsamy Padmaja Udayakumar Muthukrishnan Soundararajan Shrinivas D. Joshi Suresh Ramalingam Damodar Nayak Ammunje 《Drug development research》2019,80(3):368-385
Hit, Lead & Candidate Discovery |